WCISU ANNUAL PUBLICATION

No. SA6/01

Cancer Incidence in Wales 2000-2004

19th April 2006

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

TABLE OF CONTENTS
1.

FOREWORD ............................................................................................................ 2

2.

REGISTRATION OF CANCER IN WALES.............................................................. 3

3.

4.

2.1

ONS SUBMISSION ........................................................................................... 4

2.2

DATA QUALITY ................................................................................................ 4

DEFINITIONS AND STATISTICAL METHODS....................................................... 5

3.1

CALCULATION OF INCIDENCE RATES AND AGE STANDARDISATION...... 5

3.2

STANDARD POPULATIONS ............................................................................ 5

INCIDENCE FIGURES IN WALES BY SEX AND FIVE YEAR AGE GROUP 2004 7
4.1

MALES .............................................................................................................. 7

4.2

FEMALES ......................................................................................................... 8

5.

TRENDS IN WALES 2000-2004 .............................................................................. 9

6.

CRUDE RATES PER 100,000 POPULATION IN WALES 2000-2004 .................. 10

7.

EASR PER 100,000 POPULATION IN WALES 2000-2004 .................................. 11

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

1.

FOREWORD

The Welsh Cancer Intelligence & Surveillance Unit (WCISU) has published Cancer Incidence
Statistics for the diagnosis year 2004. As we have previously noted cancer registration is a
dynamic process based upon the consolidation of multiple sources of data on patient contacts
with the database. There is an ongoing process of statistical analysis and case note validation.

Previously in 2005 we reported our concerns with the PEDW data stream. This is not a purpose
made extract as used in most other registries but a routine dataflow based on PAS systems.
Changes in clinical practice may impact on codes e.g. transfer from inpatient or day case to
outpatient, with consequences for data capture. Resource limitations in Trusts may delay
transfers. WCISU have to filter off the relevant new data posing a considerable burden of data
processing.

However PEDW is an invaluable source of data especially on demographics and in collaboration

with Trusts, WCISU provides valuable feedback on Quality Assurance which hopefully enhances
its value for other users.

We are now receiving our first data flows from CaNISC, the all Wales cancer information system
now under the auspices of Informing Health Care. This should enable us to provide better quality
clinical data.

Our impression of these 2004 data is that the majority of sites are well within tolerance as
compared to the situation with the 2003 data and we are happy to publish them.

I thank the other members of the team for all their hard work and diligence in getting these
figures prepared.

J A Steward MBBCh BA MSc PhD FFPH

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

2.

REGISTRATION OF CANCER IN WALES

The Welsh Cancer Intelligence and Surveillance Unit (WCISU) is tasked under its SLA with the
Welsh Assembly Government to register all incidence of cancer for the resident population of
Wales wherever they are treated. It is essential therefore to ensure completeness of registration
that all possible sources of data collection are used. The use of multiple sources of data means
that information relating to the same cancer incidence is received, and this also enhances the
data quality as different data items are brought together to form a single record. WCISU benefits
from a sophisticated computer package and a highly trained workforce to ensure that duplicate
registrations are avoided.
For the most recent year reported (2004) multiple notifications were received from:

PEDW * records

Pathology records
Extra Regional Notification
ONS **

: Trusts throughout Wales

: NHS Clearing Service
: 13/14 Trusts
: Cancer Deaths
: Non Cancer Deaths

* Patient Episode Database Wales

** Office of National Statistics
Table 1 illustrates the number of records processed for the calendar year 2004. Electronic
processing and manual intervention by registration officers provide the resulting registrations for
2004 incidence.

Table 1: Notification received by WCISU 2004

SOURCE
PEDW - Wales data
- English data
Pathology
Other Registries
Death Certificates:
Cancer
Non Cancer

NUMBER OF RECORDS RECEIVED

347960*
NA
52454
NA

Total Records Received

Resulting in:
Total Registration
All Malignancies ex. skin

414429

9622
4393

23874
20868

* Figures are high due to resubmissions from NHS Trusts.

NA Not available at time of publication

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

2.1

ONS SUBMISSION

During the first years after being established WCISUs emphasis was concentrated on
timeliness. However since the inherited backlog of data has been cleared more time and
resource has been given to ensuring the quality, not only of the data currently being registered,
but also of previous registrations.
Registrations are submitted to ONS to enable flagging on NHS CR which in turn enables cancer
registries to receive Death Certificate Information. Cancer Registries are expected to have no
more than 0.5% status 3 records (ie. records containing serious errors) for each year submitted.
Good quality record submission enables a high percentage of records to be traced on NHSCR.
Table 2 shows WCISU submission to ONS and also is an indicator of the work that has been
undertaken to assure its quality.

Table 2: WCISU submissions to ONS

Year of Diagnosis
2000
2001
2002
2003
2004
*

Registrations*
15,416
15,583
15,602
16,113
16,587

Status 3 %
0.0
0.0
0.0
0.0
0.0

Traced records %
99.9
99.9
99.7
99.8
94.1

All malignancies ex. Skin (C44) and all D codes

Source : ONS Management Report, December 2005

2.2

DATA QUALITY

The quality of the information produced by WCISU can only be maintained at the highest level if
all staff are involved in ensuring data quality at every process undertaken.

Validation rules are embedded into the software used for registration and these are
reviewed in conjunction with the United Kingdom association of Cancer Registries and
the Office for National Statistics and updated as necessary.

Quality checks are run on incoming data to identify any quality issues.

Multiple sources of data are used for registration and any discrepancies between data
sources are investigated to ensure data quality.

Regular data validation is undertaken by the Units staff who access original source
documentation at hospitals by accessing medical records and verifying data received.

Analysis of data in response to requests for information and in preparation of publications

includes analysis staff in the quality program by highlighting any anomalies in the data
that are then passed for further validation.

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

In an effort to maintain good standards of incoming data, WCISU has developed and delivered
training packages to cancer information staff across Wales. Staff from the Unit who have been
trained as Clinical Coding Tutors also participate in the delivery of basic clinical coding to staff
across Wales and jointly develop, with the All Wales Coding Tutor, neoplasm workshops as
further training for coding staff.

3.

DEFINITIONS AND STATISTICAL METHODS

3.1

CALCULATION OF INCIDENCE RATES AND AGE STANDARDISATION

Crude Rate: This is the total number of cases registered per year as a proportion of the total
population. It is usually quoted per 100,000 population.
Rates for older age groups are in general, much higher than those for younger people, so that
the crude rate for an area is very much influenced by the age structure of the population of that
area. This means that comparisons of the crude rates between populations with different age
structures can be misleading. For this reason, methods have been developed to agestandardise cancer incidence rates.
Direct Standardisation: Age specific incidence rates from the population under study are
applied to a standard reference population to obtain the number of cases that would arise in the
standard population in each group. These are summed to obtain the overall directly
standardised incidence rate expressed per 100,000 population.
The standard hypothetical population used in this report the "European Standard Population"
is shown in Table 3:

3.2

STANDARD POPULATIONS

The European Age Standardised Rate (E.A.S.R.) for Wales per 100,000 population is calculated
by applying age specific rates for Wales to the relevant standard European population shown
above. These are then summed across all age groups to obtain the overall E.A.S.R.
Because the age structure of the Welsh population differs from that of the European standard
population, the standardised rate for Wales, for any particular type of cancer will differ from the
crude rate. In general, because the Welsh population is slightly older than the European
standard, the effect will be to lower the crude rate.

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

Table 3: European Standard Population

Age Group
Under 5
5-9
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85 and over
All ages

European
8000
7000
7000
7000
7000
7000
7000
7000
7000
7000
7000
6000
5000
4000
3000
2000
1000
1000
100,000

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

4.

INCIDENCE FIGURES IN WALES BY SEX AND FIVE YEAR AGE GROUP 2004

4.1

MALES

ICD10 Code
C00-C14
C00
C01-C02
C03-C06
C07-C08
C09-C10
C11
C12-C13
C14
C15
C16
C17
C18-C21
C18
C19-C21
C22
C23-C24
C25
C26
C30-C31
C32
C33-C34
C37-C39, C45
C40-C41
C43
C48
C47, C49
C50
C60, C63
C61
C62
C64-C66, C68
C67
C69
C70, C72
C71
C73
C74-C75
C76-C80
C81
C82-C85, C96
C88, C90
C91-C95
C (exc C44)

Site
Total lip, oral cavity and pharynx
Lip
Tongue
Mouth
Salivary glands
Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspecified
Oesophagus
Stomach
Small intestine
Colorectal
Colon
Rectum
Liver and intrahepatic bile ducts
Gallbladder
Pancreas
Digestive organs unspecified
Nasal cavities
Larynx
Lung
Respiratory system
Bone
Malignant melanoma of skin
Retroperitoneum and peritoneum
Connective Tissue
Breast
Penis
Prostate
Testis
Kidney
Bladder
Eye and adnexa
Other nervous system
Brain
Thyroid gland
Other endocrine glands
Other and unspecified
Hodgkin's disease
Non Hodgkins Lymphoma
Multiple myeloma
Total Leukaemia
Total of all neoplasms (excluding NMSC)

0-4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
1
0
0
0
2
2
0
1
0
2
0
0
1
0
0
0
5
15

5-9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
2
4
0
1
0
0
1
0
6
15

10-14
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5
0
0
1
0
0
0
0
1
0
0
0
3
0
1
0
1
0
0
4
16

15-19
1
0
1
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
2
1
0
0
0
0
0
1
0
0
1
1
0
0
1
0
7
4
0
2
22

20-24
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
1
0
0
0
0
0
0
0
1
2
0
0
0
0
0
8
0
0
0
0
4
0
1
1
3
3
1
5
31

25-29
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
3
0
0
0
0
0
14
0
0
0
0
4
0
0
1
2
4
0
2
32

NMSC Non-melanoma skin cancer

30-34
0
0
0
0
0
0
0
0
0
0
1
0
3
3
0
0
0
1
0
1
1
0
0
2
5
0
2
0
0
0
20
1
1
2
0
3
1
0
1
2
6
1
2
57

35-39
3
0
1
2
0
0
0
0
0
3
5
0
2
2
0
0
0
4
0
0
1
2
2
0
11
0
1
0
2
1
17
6
6
0
0
5
1
0
0
5
7
2
1
87

40-44
12
0
2
4
0
6
0
0
0
3
0
1
12
5
7
2
1
3
1
0
1
10
0
1
15
2
2
1
0
1
11
8
1
2
1
2
2
0
5
1
10
5
7
124

45-49
18
1
7
3
0
4
1
2
0
13
8
0
23
13
10
4
1
5
0
3
5
14
1
0
14
0
2
2
2
9
6
10
10
1
0
5
1
0
10
2
14
4
6
193

50-54
33
4
9
11
1
4
0
2
2
8
17
1
46
26
20
4
0
7
1
0
6
41
2
1
26
1
2
0
4
48
2
18
25
2
0
8
3
1
12
3
15
4
8
349

55-59
34
2
8
6
2
10
0
4
2
21
25
3
94
46
48
12
3
20
2
1
9
127
13
1
21
1
5
1
0
155
3
31
44
5
0
18
2
1
26
4
29
21
9
741

60-64
31
1
14
6
1
6
0
3
0
29
34
2
124
74
50
13
1
20
4
3
18
136
16
2
16
1
5
1
2
267
3
34
77
2
0
18
1
1
34
5
40
7
25
972

65-69
29
2
8
6
2
5
2
3
1
36
42
4
158
94
64
16
2
32
1
3
15
212
19
2
19
1
4
2
1
366
2
39
117
3
1
27
8
0
45
0
36
15
41
1298

70-74
17
1
4
5
2
0
0
3
2
36
47
6
197
107
90
14
5
33
2
1
12
250
16
0
28
2
6
0
2
420
0
45
107
1
0
16
2
1
58
2
42
35
46
1449

75-79
12
0
2
3
3
1
0
1
2
37
42
2
214
131
83
17
8
40
7
1
13
241
9
3
29
0
6
2
4
451
1
35
120
1
1
16
2
2
59
4
32
18
47
1476

80-84
11
1
1
3
2
1
1
1
1
43
52
3
171
111
60
19
2
29
2
1
8
167
10
2
12
1
6
5
3
346
2
28
101
2
1
6
0
0
48
1
21
27
42
1172

85+
16
7
2
1
5
0
1
0
0
23
37
3
95
56
39
3
5
24
3
0
2
111
6
3
12
0
0
5
8
224
1
11
67
0
0
7
2
0
41
2
14
14
27
766

TOTAL
217
19
59
50
18
37
5
19
10
252
310
25
1140
669
471
107
28
218
23
14
91
1312
95
25
214
9
43
19
28
2288
94
269
676
23
7
148
25
10
342
44
278
154
285
8815

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

4.2

FEMALES

ICD10 Code
C00-C14
C00
C01-C02
C03-C06
C07-C08
C09-C10
C11
C12-C13
C14
C15
C16
C17
C18-C21
C18
C19-C21
C22
C23-C24
C25
C26
C30-C31
C32
C33-C34
C37-C39, C45
C40-C41
C43
C48
C47, C49
C50
C51-C52
C53
C54
C55
C56-C57
C58
C64-C66, C68
C67
C69
C70, C72
C71
C73
C74-C75
C76-C80
C81
C82-C85, C96
C88, C90
C91-C95
C (exc C44)

Site
Total lip, oral cavity and pharynx
Lip
Tongue
Mouth
Salivary glands
Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspecified
Oesophagus
Stomach
Small intestine
Colorectal
Colon
Rectum
Liver and intrahepatic bile ducts
Gallbladder
Pancreas
Digestive organs unspecified
Nasal cavities
Larynx
Lung
Respiratory system
Bone
Malignant melanoma of skin
Retroperitoneum and peritoneum
Connective Tissue
Breast
Other female genital
Cervix Uteri
Corpus Uteri
Uterus, part unspecified
Ovary
Placenta
Kidney
Bladder
Eye and adnexa
Other nervous system
Brain
Thyroid gland
Other endocrine glands
Other and unspecified
Hodgkin's disease
Non Hodgkins Lymphoma
Multiple myeloma
Total Leukaemia
Total of all neoplasms (excluding NMSC)

0-4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
2
0
2
0
1
0
0
0
0
6
13

5-9
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
1
0
0
1
2
0
0
1
0
1
0
2
10

10-14
1
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
2
1
0
1
1
0
0
3
11

15-19
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
0
1
3
0
0
0
0
0
0
0
0
0
1
2
3
0
0
3
1
0
2
20

20-24
0
0
0
0
0
0
0
0
0
0
0
0
2
0
2
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
3
0
0
0
0
0
0
3
0
0
2
3
0
2
16

25-29
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
1
7
0
1
6
1
4
1
0
3
0
3
0
0
0
2
6
0
0
3
0
0
1
40

NMSC Non-melanoma skin cancer

30-34
2
0
0
0
1
1
0
0
0
0
0
0
1
0
1
1
0
0
0
0
0
0
0
0
10
0
2
29
0
12
0
0
6
1
2
2
0
0
2
2
0
1
1
3
1
2
80

35-39
0
0
0
0
0
0
0
0
0
0
0
0
7
6
1
0
0
2
0
2
1
4
1
0
13
0
0
71
1
25
1
0
9
0
2
1
0
0
5
4
0
5
3
1
1
2
161

40-44
5
0
0
2
1
2
0
0
0
2
1
0
13
9
4
1
0
6
0
0
1
9
0
0
17
0
2
142
3
15
8
1
13
0
1
2
0
1
6
1
0
2
3
7
0
8
270

45-49
9
0
4
3
0
2
0
0
0
2
6
0
22
13
9
2
4
4
0
1
1
17
0
1
19
0
2
165
3
17
14
2
17
0
6
8
0
0
5
8
1
7
0
12
3
4
362

50-54
9
0
1
3
2
3
0
0
0
5
5
5
47
29
18
2
1
9
0
1
1
41
0
1
20
0
4
232
3
16
31
4
22
1
6
7
1
1
7
5
1
13
4
16
6
6
533

55-59
9
1
4
2
1
0
0
1
0
8
7
0
59
36
23
2
1
18
0
1
2
69
4
1
32
0
3
288
4
18
52
3
46
0
11
15
2
0
6
3
1
23
0
22
10
16
736

60-64
18
0
2
4
2
5
0
3
2
15
12
3
81
47
34
10
5
21
0
0
3
116
3
2
18
4
3
300
4
11
68
1
48
0
19
23
4
0
5
2
1
33
1
13
15
11
873

65-69
9
0
6
0
0
1
1
1
0
15
19
1
97
63
34
8
1
12
2
2
1
117
2
0
21
0
1
260
4
7
59
3
51
0
25
31
5
1
9
3
0
37
1
23
18
32
877

70-74
7
0
1
3
1
1
0
1
0
19
34
5
126
95
31
13
5
36
1
1
5
164
2
1
18
0
2
220
18
13
54
1
43
0
28
33
0
0
13
4
2
50
2
36
11
25
992

75-79
12
2
2
7
0
0
0
1
0
22
40
3
157
117
40
8
4
38
6
2
3
210
2
0
18
3
7
190
17
11
46
1
33
0
28
42
2
0
15
2
3
67
1
42
20
39
1094

80-84
7
1
0
2
2
0
0
1
1
29
56
1
173
119
54
16
4
51
7
1
2
125
1
2
15
2
5
212
21
2
33
3
38
0
20
43
2
1
7
4
3
74
2
35
14
23
1034

85+
10
1
3
3
2
0
0
1
0
35
38
4
134
89
45
13
11
37
11
1
3
64
1
3
21
1
5
196
16
6
18
5
36
0
14
46
1
1
5
2
1
103
1
21
30
31
925

TOTAL
98
5
23
29
12
15
2
9
3
153
218
22
919
623
296
76
36
234
27
12
23
936
16
14
233
10
40
2314
95
157
385
24
369
2
168
253
19
7
95
53
14
417
28
236
129
215
8047

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

5.

TRENDS IN WALES 2000-2004

Incidence figures (all ages)

ICD10 Code
C00-C14
C00
C01-C02
C03-C06
C07-C08
C09-C10
C11
C12-C13
C14
C15
C16
C17
C18-C21
C18
C19-C21
C22
C23-C24
C25
C26
C30-C31
C32
C33-C34
C37-C39, C45
C40-C41
C43
C48
C47, C49
C50
C51-C52
C53
C54
C55
C56-C57
C58
C60, C63
C61
C62
C64-C66, C68
C67
C69
C70, C72
C71
C73
C74-C75
C76-C80
C81
C82-C85, C96
C88, C90
C91-C95
C (exc C44)

Site
Total lip, oral cavity and pharynx
Lip
Tongue
Mouth
Salivary glands
Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspecified
Oesophagus
Stomach
Small intestine
Colorectal
Colon
Rectum
Liver and intrahepatic bile ducts
Gallbladder
Pancreas
Digestive organs unspecified
Nasal cavities
Larynx
Lung
Respiratory system
Bone
Malignant melanoma of skin
Retroperitoneum and peritoneum
Connective Tissue
Breast
Other female genital
Cervix Uteri
Corpus Uteri
Uterus, part unspecified
Ovary
Placenta
Penis
Prostate
Testis
Kidney
Bladder
Eye and adnexa
Other nervous system
Brain
Thyroid gland
Other endocrine glands
Other and unspecified
Hodgkin's disease
Non Hodgkins Lypmphoma
Multiple myeloma
Total Leukaemia
Total of all neoplasms (excluding NMSC)

2000
188
16
46
36
24
33
7
19
7
263
374
17
1114
658
456
72
29
194
8
14
122
1287
83
17
164
8
45
13
29
1647
75
221
636
25
7
149
20
7
329
46
208
139
225
7775

2001
183
25
43
45
13
31
4
17
5
291
369
17
1087
640
447
76
42
175
17
11
99
1323
90
18
172
6
56
24
22
1771
81
252
662
24
9
145
16
7
303
56
251
177
247
8079

NMSC Non-melanoma skin cancer

MALES
2002
189
27
33
46
15
26
16
18
8
250
351
17
1052
600
452
86
23
204
14
16
108
1248
69
15
178
5
61
16
22
1798
86
240
605
19
5
136
28
11
326
43
268
153
265
7907

2003
179
9
43
55
13
24
13
18
4
271
373
28
1130
678
452
104
27
203
13
7
92
1283
79
16
196
9
51
16
25
2002
112
232
636
29
2
125
26
5
329
49
287
164
265
8365

2004
217
19
59
50
18
37
5
19
10
252
310
25
1140
669
471
107
28
218
23
14
91
1312
95
25
214
9
43
19
28
2288
94
269
676
23
7
148
25
10
342
44
278
154
285
8815

2000
113
14
22
29
23
7
3
11
4
187
236
16
891
591
300
64
51
201
21
10
21
827
22
14
199
10
41
2124
92
164
325
40
408
1
140
261
24
7
104
41
7
400
34
217
106
181
7600

2001
113
11
23
30
18
12
2
11
6
165
219
23
870
572
298
70
60
223
17
11
24
868
14
14
203
15
34
2130
96
153
344
23
383
1
133
244
21
9
101
51
14
375
25
243
136
180
7605

FEMALES
2002
113
7
30
27
22
8
4
11
4
187
202
24
888
592
296
59
40
216
18
11
23
848
22
6
252
16
32
2318
91
148
318
27
408
1
158
248
22
6
119
58
16
372
31
252
114
193
7857

2003
92
5
16
27
13
14
5
6
6
159
213
22
881
567
314
54
34
236
13
12
16
820
24
14
239
10
38
2355
79
158
338
23
424
2
163
248
25
9
118
41
10
365
29
247
131
191
7833

2004
98
5
23
29
12
15
2
9
3
153
218
22
919
623
296
76
36
234
27
12
23
936
16
14
233
10
40
2314
95
157
385
24
369
2
168
253
19
7
95
53
14
417
28
236
129
215
8047

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

6.

CRUDE RATES PER 100,000 POPULATION IN WALES 2000-2004

ICD10 Code
C00-C14
C00
C01-C02
C03-C06
C07-C08
C09-C10
C11
C12-C13
C14
C15
C16
C17
C18-C21
C18
C19-C21
C22
C23-C24
C25
C26
C30-C31
C32
C33-C34
C37-C39, C45
C40-C41
C43
C48
C47, C49
C50
C51-C52
C53
C54
C55
C56-C57
C58
C60, C63
C61
C62
C64-C66, C68
C67
C69
C70, C72
C71
C73
C74-C75
C76-C80
C81
C82-C85, C96
C88, C90
C91-C95
C (exc C44)

Site
Total lip, oral cavity and pharynx
Lip
Tongue
Mouth
Salivary glands
Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspecified
Oesophagus
Stomach
Small intestine
Colorectal
Colon
Rectum
Liver and intrahepatic bile ducts
Gallbladder
Pancreas
Digestive organs unspecified
Nasal cavities
Larynx
Lung
Respiratory system
Bone
Malignant melanoma of skin
Retroperitoneum and peritoneum
Connective Tissue
Breast
Other female genital
Cervix Uteri
Corpus Uteri
Uterus, part unspecified
Ovary
Placenta
Penis
Prostate
Testis
Kidney
Bladder
Eye and adnexa
Other nervous system
Brain
Thyroid gland
Other endocrine glands
Other and unspecified
Hodgkin's disease
Non Hodgkins Lypmphoma
Multiple myeloma
Total Leukaemia
Total of all neoplasms (excluding NMSC)

2000
13.4
1.1
3.3
2.6
1.7
2.3
0.5
1.3
0.5
18.7
26.6
1.2
79.1
46.7
32.4
5.1
2.1
13.8
0.6
1.0
8.7
91.4
5.9
1.2
11.6
0.6
3.2
0.9
2.1
117.0
5.3
15.7
45.2
1.8
0.5
10.6
1.4
0.5
23.4
3.3
14.8
9.9
16.0
552.2

2001
13.0
1.8
3.1
3.2
0.9
2.2
0.3
1.2
0.4
20.7
26.2
1.2
77.2
45.4
31.7
5.4
3.0
12.4
1.2
0.8
7.0
93.9
6.4
1.3
12.2
0.4
4.0
1.7
1.6
125.7
5.8
17.9
47.0
1.7
0.6
10.3
1.1
0.5
21.5
4.0
17.8
12.6
17.5
573.7

NMSC Non-melanoma skin cancer

10

MALES
2002
13.4
1.9
2.3
3.3
1.1
1.8
1.1
1.3
0.6
17.7
24.8
1.2
74.4
42.4
32.0
6.1
1.6
14.4
1.0
1.1
7.6
88.3
4.9
1.1
12.6
0.4
4.3
1.1
1.6
127.2
6.1
17.0
42.8
1.3
0.4
9.6
2.0
0.8
23.1
3.0
19.0
10.8
18.7
559.4

2003
12.6
0.6
3.0
3.9
0.9
1.7
0.9
1.3
0.3
19.0
26.2
2.0
79.3
47.6
31.7
7.3
1.9
14.2
0.9
0.5
6.5
90.0
5.5
1.1
13.7
0.6
3.6
1.1
1.8
140.4
7.9
16.3
44.6
2.0
0.1
8.8
1.8
0.4
23.1
3.4
20.1
11.5
18.6
586.9

2004
15.1
1.3
4.1
3.5
1.3
2.6
0.3
1.3
0.7
17.6
21.6
1.7
79.5
46.6
32.8
7.5
2.0
15.2
1.6
1.0
6.3
91.5
6.6
1.7
14.9
0.6
3.0
1.3
2.0
159.5
6.6
18.8
47.1
1.6
0.5
10.3
1.7
0.7
23.8
3.1
19.4
10.7
19.9
614.6

2000
7.5
0.9
1.5
1.9
1.5
0.5
0.2
0.7
0.3
12.5
15.7
1.1
59.4
39.4
20.0
4.3
3.4
13.4
1.4
0.7
1.4
55.2
1.5
0.9
13.3
0.7
2.7
141.7
6.1
10.9
21.7
2.7
27.2
0.1
9.3
17.4
1.6
0.5
6.9
2.7
0.5
26.7
2.3
14.5
7.1
12.1
507.1

2001
7.5
0.7
1.5
2.0
1.2
0.8
0.1
0.7
0.4
11.0
14.6
1.5
57.9
38.1
19.8
4.7
4.0
14.9
1.1
0.7
1.6
57.8
0.9
0.9
13.5
1.0
2.3
141.9
6.4
10.2
22.9
1.5
25.5
0.1
8.9
16.2
1.4
0.6
6.7
3.4
0.9
25.0
1.7
16.2
9.1
12.0
506.5

FEMALES
2002
7.5
0.5
2.0
1.8
1.5
0.5
0.3
0.7
0.3
12.4
13.4
1.6
58.8
39.2
19.6
3.9
2.6
14.3
1.2
0.7
1.5
56.2
1.5
0.4
16.7
1.1
2.1
153.6
6.0
9.8
21.1
1.8
27.0
0.1
10.5
16.4
1.5
0.4
7.9
3.8
1.1
24.6
2.1
16.7
7.6
12.8
520.6

2003
6.1
0.3
1.1
1.8
0.9
0.9
0.3
0.4
0.4
10.5
14.1
1.5
58.3
37.5
20.8
3.6
2.2
15.6
0.9
0.8
1.1
54.2
1.6
0.9
15.8
0.7
2.5
155.7
5.2
10.4
22.3
1.5
28.0
0.1
10.8
16.4
1.7
0.6
7.8
2.7
0.7
24.1
1.9
16.3
8.7
12.6
517.9

2004
6.5
0.3
1.5
1.9
0.8
1.0
0.1
0.6
0.2
10.1
14.4
1.4
60.5
41.0
19.5
5.0
2.4
15.4
1.8
0.8
1.5
61.7
1.1
0.9
15.3
0.7
2.6
152.4
6.3
10.3
25.4
1.6
24.3
0.1
11.1
16.7
1.3
0.5
6.3
3.5
0.9
27.5
1.8
15.5
8.5
14.2
530.1

Welsh Cancer Intelligence & Surveillance Unit Uned Arolygiaeth a Gwybodaeth Cymru

7.

EASR PER 100,000 POPULATION IN WALES 2000-2004

ICD10 Code
C00-C14
C00
C01-C02
C03-C06
C07-C08
C09-C10
C11
C12-C13
C14
C15
C16
C17
C18-C21
C18
C19-C21
C22
C23-C24
C25
C26
C30-C31
C32
C33-C34
C37-C39, C45
C40-C41
C43
C48
C47, C49
C50
C51-C52
C53
C54
C55
C56-C57
C58
C60, C63
C61
C62
C64-C66, C68
C67
C69
C70, C72
C71
C73
C74-C75
C76-C80
C81
C82-C85, C96
C88, C90
C91-C95
C (exc C44)

Site
Total lip, oral cavity and pharynx
Lip
Tongue
Mouth
Salivary glands
Oropharynx
Nasopharynx
Hypopharynx
Pharynx unspecified
Oesophagus
Stomach
Small intestine
Colorectal
Colon
Rectum
Liver and intrahepatic bile ducts
Gallbladder
Pancreas
Digestive organs unspecified
Nasal cavities
Larynx
Lung
Respiratory system
Bone
Malignant melanoma of skin
Retroperitoneum and peritoneum
Connective Tissue
Breast
Other female genital
Cervix Uteri
Corpus Uteri
Uterus, part unspecified
Ovary
Placenta
Penis
Prostate
Testis
Kidney
Bladder
Eye and adnexa
Other nervous system
Brain
Thyroid gland
Other endocrine glands
Other and unspecified
Hodgkin's disease
Non Hodgkins Lypmphoma
Multiple myeloma
Total Leukaemia
Total of all neoplasms (excluding NMSC)

2000
11.7
0.9
2.9
2.3
1.4
2.2
0.4
1.1
0.4
15.3
20.3
1.0
62.4
36.5
25.9
4.1
1.6
11.1
0.5
0.9
7.2
71.4
4.6
1.2
10.0
0.5
2.8
0.8
1.8
88.7
5.4
13.1
35.5
1.5
0.5
9.4
1.3
0.5
17.9
3.1
12.8
7.8
13.4
440.2

2001
11.1
1.4
2.5
2.9
0.7
2.0
0.2
1.1
0.3
16.3
20.5
1.0
60.5
35.4
25.1
4.2
2.3
9.8
0.8
0.7
5.7
71.3
5.4
1.2
10.8
0.4
3.3
1.3
1.4
93.8
6.0
14.8
36.3
1.5
0.5
9.0
1.0
0.5
16.6
3.8
15.0
9.7
14.2
451.0

MALES
2002
11.2
1.5
2.0
2.8
0.7
1.6
1.0
1.1
0.5
13.8
18.6
1.0
57.4
32.2
25.2
4.7
1.3
11.0
0.7
0.9
6.5
67.2
3.7
1.0
10.7
0.3
3.5
0.9
1.3
94.9
6.3
13.8
32.7
1.1
0.3
8.3
1.8
0.7
17.4
3.0
15.5
8.3
14.9
434.9

EASR European Age Standardised Rate per 100,000 population

NMSC Non-melanoma skin cancer

11

2003
10.9
0.5
2.7
3.3
0.8
1.5
0.9
1.1
0.2
14.9
19.5
1.7
60.6
36.0
24.7
5.8
1.6
10.9
0.7
0.4
5.3
67.7
4.1
1.1
11.6
0.5
3.0
0.9
1.5
103.9
8.4
13.1
33.8
1.8
0.1
7.8
1.7
0.3
17.6
3.3
16.5
8.8
14.8
454.7

2004
13.1
1.2
3.7
3.1
1.0
2.3
0.3
1.1
0.5
13.3
16.3
1.3
59.2
34.5
24.8
5.7
1.5
11.5
1.2
0.8
5.1
68.3
5.2
1.5
12.7
0.5
2.4
1.0
1.6
116.5
6.9
14.9
35.1
1.4
0.4
8.9
1.5
0.6
18.0
2.9
16.0
8.0
15.4
469.3

2000
5.4
0.6
1.2
1.2
1.1
0.4
0.2
0.5
0.2
7.5
8.9
0.7
37.1
24.1
13.0
2.5
2.1
7.9
1.0
0.5
1.0
36.8
0.9
0.9
10.7
0.6
2.2
113.3
3.9
9.4
16.3
1.8
21.0
0.1
6.6
11.1
1.0
0.4
5.8
2.3
0.5
16.4
2.1
10.4
4.6
8.8
362.4

2001
5.8
0.4
1.3
1.5
1.0
0.6
0.1
0.5
0.3
6.8
8.3
1.2
35.7
23.4
12.3
2.8
2.3
8.2
0.5
0.5
1.1
37.9
0.7
0.8
10.9
0.9
1.6
113.0
4.1
9.1
17.8
1.1
19.2
0.1
6.4
10.2
1.0
0.5
5.7
3.0
0.9
13.9
1.7
11.0
5.9
7.8
358.3

FEMALES
2002
5.5
0.3
1.4
1.3
1.1
0.5
0.2
0.5
0.2
7.1
7.8
1.2
36.3
23.4
12.9
2.6
1.8
8.4
0.5
0.5
1.1
36.9
1.1
0.3
13.9
0.9
1.7
120.7
3.8
8.7
15.7
1.1
21.1
0.1
7.3
9.6
1.1
0.3
6.5
3.5
1.0
13.4
2.0
12.1
4.7
9.0
369.6

2003
4.8
0.2
0.9
1.4
0.6
0.9
0.3
0.3
0.3
5.9
8.0
0.9
35.6
22.0
13.6
2.2
1.3
9.6
0.4
0.7
0.8
35.9
1.1
0.8
13.1
0.5
2.0
120.9
3.5
9.3
16.2
1.0
20.7
0.2
7.9
10.0
1.5
0.5
6.1
2.4
0.7
14.2
2.0
11.5
5.1
8.3
365.6

2004
5.0
0.2
1.2
1.4
0.6
1.0
0.1
0.4
0.1
5.8
7.8
1.0
37.2
24.8
12.5
3.0
1.5
9.1
0.7
0.6
1.1
40.4
0.8
0.7
12.6
0.4
2.0
118.4
3.6
9.4
19.1
1.1
18.1
0.1
7.8
10.1
1.0
0.4
5.0
3.3
0.6
15.7
1.8
10.6
5.3
9.8
370.9